PL336233A1 - Compounds and agents for treating diseases associated with serinic protease activity, in particular tryptase activity - Google Patents

Compounds and agents for treating diseases associated with serinic protease activity, in particular tryptase activity

Info

Publication number
PL336233A1
PL336233A1 PL97336233A PL33623397A PL336233A1 PL 336233 A1 PL336233 A1 PL 336233A1 PL 97336233 A PL97336233 A PL 97336233A PL 33623397 A PL33623397 A PL 33623397A PL 336233 A1 PL336233 A1 PL 336233A1
Authority
PL
Poland
Prior art keywords
activity
serinic
agents
compounds
diseases associated
Prior art date
Application number
PL97336233A
Other languages
English (en)
Inventor
Timothy J Church
Neil Scott Cutshall
Anthony R Gangloff
Thomas E Jenkins
Martin S Linsell
Joane Litvak
Kenneth D Rice
Jeffrey R Spencer
Vivian R Wang
Original Assignee
Axys Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc filed Critical Axys Pharm Inc
Publication of PL336233A1 publication Critical patent/PL336233A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL97336233A 1997-04-07 1997-12-01 Compounds and agents for treating diseases associated with serinic protease activity, in particular tryptase activity PL336233A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83367497A 1997-04-07 1997-04-07
PCT/US1997/021849 WO1998045275A1 (en) 1997-04-07 1997-12-01 Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity

Publications (1)

Publication Number Publication Date
PL336233A1 true PL336233A1 (en) 2000-06-19

Family

ID=25264996

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97336233A PL336233A1 (en) 1997-04-07 1997-12-01 Compounds and agents for treating diseases associated with serinic protease activity, in particular tryptase activity

Country Status (16)

Country Link
EP (1) EP1019382A1 (xx)
JP (1) JP2001519806A (xx)
KR (1) KR20010006119A (xx)
CN (1) CN1251579A (xx)
AU (1) AU752064B2 (xx)
CA (1) CA2285454A1 (xx)
EE (1) EE04055B1 (xx)
HU (1) HUP0001522A3 (xx)
LT (1) LT4704B (xx)
LV (1) LV12495B (xx)
NO (1) NO314183B1 (xx)
NZ (1) NZ500029A (xx)
PL (1) PL336233A1 (xx)
SI (1) SI20115A (xx)
SK (1) SK136799A3 (xx)
WO (1) WO1998045275A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
WO1999026932A1 (en) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. By amidino group substituted heterocyclic derivatives and their use as anticoagulants
WO1999026933A1 (en) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants
GT199900167A (es) * 1998-10-01 2001-03-21 Nuevos bis-benzimidazoles.
WO2000020400A1 (en) * 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
JP2003501418A (ja) * 1999-06-04 2003-01-14 エラン ファーマ インターナショナル,リミティド 細胞死を阻害するための組成物および方法
DE19953899A1 (de) * 1999-11-10 2001-05-17 Boehringer Ingelheim Pharma Carboxamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2001052883A1 (en) * 2000-01-20 2001-07-26 Amgen Inc. Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
DE10048715A1 (de) * 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
JP4176477B2 (ja) * 2001-03-01 2008-11-05 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有する含窒素芳香族複素環誘導体
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
DE102011111991A1 (de) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
MX349514B (es) * 2011-11-29 2017-08-02 Perosphere Inc Agentes de reversion anticoagulante.
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
US20220235070A1 (en) * 2019-05-21 2022-07-28 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105837A (en) * 1961-10-20 1963-10-01 Upjohn Co 2, 2'-alkylenebisbenzimidazoles
US3210370A (en) * 1964-06-22 1965-10-05 Upjohn Co Process for preparing 2, 2'-methylene-bisareneimiazoles
AU7661594A (en) * 1993-09-22 1995-04-10 Glaxo Wellcome House Bis(amidinobenzimidazolyl)alkanes as antiviral agents
US6815461B1 (en) * 1994-01-20 2004-11-09 The University Of North Carolina At Chapel Hill Method of inhibiting retroviral integrase
US5693515A (en) * 1995-04-28 1997-12-02 Arris Pharmaceutical Corporation Metal complexed serine protease inhibitors

Also Published As

Publication number Publication date
NZ500029A (en) 2001-02-23
SK136799A3 (en) 2000-07-11
LV12495B (en) 2001-01-20
AU5895098A (en) 1998-10-30
JP2001519806A (ja) 2001-10-23
CA2285454A1 (en) 1998-10-15
EE9900477A (et) 2000-06-15
LT4704B (lt) 2000-09-25
NO994858D0 (no) 1999-10-06
HUP0001522A3 (en) 2001-08-28
EP1019382A1 (en) 2000-07-19
KR20010006119A (ko) 2001-01-26
NO314183B1 (no) 2003-02-10
HUP0001522A2 (hu) 2001-05-28
EE04055B1 (et) 2003-06-16
CN1251579A (zh) 2000-04-26
LV12495A (en) 2000-06-20
SI20115A (sl) 2000-06-30
AU752064B2 (en) 2002-09-05
WO1998045275A1 (en) 1998-10-15
NO994858L (no) 1999-12-06
LT99131A (en) 2000-04-25

Similar Documents

Publication Publication Date Title
PL336233A1 (en) Compounds and agents for treating diseases associated with serinic protease activity, in particular tryptase activity
PL331465A1 (en) Novel compounds and agents for treating diseases associated with triptase activity
ZA9711029B (en) Therapeutic agents.
MXPA02006325A (es) Maquina precortadora y biseladora.
GB9704948D0 (en) Therapeutic agents
GB9702524D0 (en) Therapeutic agents
EP0685219A3 (de) Haarbehandlungsmittel und Verfahren zur Anwendung.
GB9711753D0 (en) Therapeutic agents
GB9713707D0 (en) Therapeutic agents
HUP0001294A3 (en) Heterocycleketo hydrazide derivatives having protease inhibitor activity, process for their preparation and their use
GB9715977D0 (en) Therapeutic agents
GB9711114D0 (en) Therapeutic agents
GB9723544D0 (en) Therapeutic agents
ZA98968B (en) Therapeutic agents
EP0921803A4 (en) METHOD FOR PREVENTING AND TREATING PESTVIRUS INFECTIONS AND RELATED DISEASES
ZA9710181B (en) Method and composition for enhancing biocidal activity.
GB9700555D0 (en) Therapeutic agents
GB9725126D0 (en) Therapeutic agents
GB9706332D0 (en) Improvements in aprons
GB9718254D0 (en) Therapeutic agents
GB9716463D0 (en) Therapeutic agents
LT99019A (en) Novel compounds and compositions for treating diseases associated with tryptase activity
IL125148A0 (en) Medicament forms constituted in situ for releasing enzymes into wounds
HK1004410A1 (en) Protein having tpo activity.
PL303548A1 (en) Method of prolongedly cannulating the pancreas, in particular that of swine, and cannule therefor